BPI-472372 / Betta Pharma - LARVOL DELTA

BPI-472372: a potent and orally bioavailable small molecule inhibitor of CD73 for cancer immunotherapy (AACR 2023) - "Moreover, enhanced tumor growth inhibition activity was observed when BPI-472372 was combined with durvalumab (anti-PD-L1) in humanized PD-L1 syngeneic MC38 model. GLP toxicity study indicated that BPI-472372 was well tolerated at high dose following 4 weeks repeated administration in both mouse and dog. Taken together, BPI-472372 is a potent and orally bioavailable small molecule CD73 inhibitor with single agent anti-tumor efficacy, favorable ADME properties, and a wide therapeutic index."

IO biomarker • Oncology • CD4 • NT5E